InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,549.26
(
-1.10%
)
Post# of 253511
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: masterlongevity post# 150443

Thursday, 10/11/2012 2:06:31 PM

Thursday, October 11, 2012 2:06:31 PM

Post# of 253511
I think bapineuzumab is out of the game and my guess is ADCS scientists await for the biomarkers data from solanezumab EXPEDITION trials and if correlate with cognitive/functional findings, it will be the one cause as you've said safety is very important here and solanezumab has more safety data which are good.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up